Digital therapeutics (DTx) startup Sidekick Health and pharmaceutical company Eli Lilly have partnered to launch a DTx product for patients diagnosed with breast cancer. The digital product will offer a personalized treatment plan with behavioral modifications to improve wellbeing and support drug treatment adherence and side effects management.
The DTx will be tailored for patients treated with Lilly’s breast cancer medication including Verzenio, a CDK 4/6 inhibitor, which is expected to launch in Germany in July 2022.
<ul><li> The latest collaboration comes hot on the heels of Sidekick’s partnership with Pfizer to develop a DTx solution targeting treatment adherence for atopic dermatitis or eczema. The company planned to announce three collaborations in the upcoming months following its funding round in May 2022 .</ul>
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.